Conference call and webcast to be held at
4:30 p.m. EDT
NEW
HAVEN, Conn., Aug. 3, 2023
/PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a
clinical-stage biopharmaceutical company developing the
investigational therapy Haduvio™ (oral nalbuphine ER) for difficult
to treat patients with chronic cough in idiopathic pulmonary
fibrosis (IPF), other chronic cough indications, and prurigo
nodularis, today announced that senior management will host a
conference call and live audio webcast on Thursday, August 10,
2023, at 4:30 p.m. ET, to provide a corporate update and
review the Company's financial results for the second quarter ended
June 30, 2023.
To participate in the live conference call by phone, please dial
(888) 317 6003 (domestic) or (412) 317 6061 (international) and
provide access code 6064699. A live audio webcast will be
accessible from the 'Investors & News' section on the Company's
website at www.TreviTherapeutics.com. An archived replay of
the webcast will also be available for 30 days on the Company's
website following the event.
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical
company developing the investigational therapy Haduvio™ (oral
nalbuphine ER) for difficult to treat patients with chronic cough
in idiopathic pulmonary fibrosis (IPF), other chronic cough
indications, and prurigo nodularis. Haduvio is a dual ĸ-opioid
receptor agonist and µ-opioid receptor antagonist that works both
centrally as well as peripherally in the lungs and has the
potential for a synergistic anti-tussive effect to treat chronic
cough.
The impact of chronic cough is significant and often leads to a
decline in patients' social, physical, and psychological quality of
life. There are no approved therapies for the treatment of chronic
cough in IPF and current treatment options provide minimal relief
to patients. In IPF, chronic cough may lead to worsening disease
and may be associated with a higher risk of progression, death, or
need for lung transplant.
Parenteral nalbuphine is not scheduled by the US Drug
Enforcement Agency. Trevi intends to propose Haduvio as the trade
name for oral nalbuphine ER. Its safety and efficacy have not been
evaluated by any regulatory authority.
For more information,
visit www.TreviTherapeutics.com and follow Trevi
on Twitter and LinkedIn.
Investor Contact
Katie
McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com
Media Contact
Rosalia
Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-to-report-q2-2023-financial-results-and-provide-a-corporate-update-on-august-10-2023-301891986.html
SOURCE Trevi Therapeutics, Inc.